日本歯科麻酔学会雑誌
Online ISSN : 2433-4480
短報
アミトリプチリン塩酸塩内服によって女性化乳房をきたした1例
金子 大黒田 英孝伊村 美希今泉 うの城戸 幹太讃岐 拓郎
著者情報
ジャーナル フリー

2023 年 51 巻 2 号 p. 39-41

詳細
抄録

  A 79-year-old man who presented with a persistent allodynia of the left face and had been diagnosed as having postherpetic neuralgia underwent a stellate ganglion block and drug therapy. The patient had a history of alcoholic hepatitis and hepatic dysfunction. The patient complained of bilateral chest lumps after the oral administration of 10 mg/day of amitriptyline hydrochloride for 9 months. Two 40 mm×40 mm swollen areas were observed, one beneath each nipple, and CT images showed two enlargements of the mammary tissue, each 15 mm×35 mm in size, with one on each side. The patient was diagnosed as having gynecomastia, and the amitriptyline hydrochloride was immediately discontinued. The gynecomastia disappeared 6 months after the discontinuation of the oral medication.

  Gynecomastia is the benign proliferation of glandular breast tissue in men and can occur physiologically or as a disease symptom. In both cases, it occurs when female hormones become absolutely and/or relatively dominant over male hormones. The secretion of prolactin, a hormone that regulates mammary gland differentiation and development, is regulated by prolactin inhibiting and prolactin releasing factor (PRF). Tricyclic antidepressants can increase the relative amount of PRF, which can in turn accelerate prolactin secretion. Estrogen, a female hormone, is metabolized by conjugation in the liver, but this patient had a history of alcoholic hepatitis and impaired liver function. Aging can also cause breast enlargement. During old age, the synthesis of androgen is decreased, and the activity of aromatase, which is an enzyme that biosynthesizes estrogen from androgens, is increased. In this case, the combination of aging, liver dysfunction, and the use of amitriptyline hydrochloride may have caused a relative dominance of female hormones, resulting in gynecomastia.

著者関連情報
© 2023 一般社団法人日本歯科麻酔学会
前の記事 次の記事
feedback
Top